Glaucoma care now offers more than a daily bottle. Briargrove Eye Center looks at sustained-release medicine, gentle laser therapy, smaller surgical options, and smart monitoring that may help selected Houston patients manage eye pressure with fewer daily steps.
A small bottle can take up a surprising amount of space in your day. Glaucoma drops call for careful timing, steady hands, fresh refills, and the right technique. Arthritis, tremors, eye irritation, travel, or a crowded medication schedule can make that routine feel even heavier.
Daily eye drops remain one of the most common glaucoma treatments. The range of advanced glaucoma care has also grown. Sustained-release eye implants can deliver medicine from inside the eye. Selective laser trabeculoplasty (SLT) can help the eye’s drainage tissue work more freely. Micro-invasive glaucoma surgery (MIGS) can create a tiny new route for fluid. Each choice fits a defined group of patients and may reduce the amount of daily treatment they handle.
People searching for glaucoma treatment without drops now have more options to discuss with their eye care team. A personal plan may include drops, an implant, laser treatment, surgery, or a thoughtful combination.
Briargrove Eye Center brings advanced technology and a warm, personal approach to ocular disease care in Uptown Houston. The practice has served patients from Tanglewood, the Galleria area, and nearby communities for more than 18 years. Dr. Shawn Muldoon provides primary eye care and ocular disease management, and he serves as an adjunct assistant professor at the University of Houston College of Optometry’s Cornea and Contact Lens Service.
The practice also uses optical coherence tomography (OCT), digital retinal imaging, visual field testing, and optomap imaging to follow eye health over time. Request a comprehensive eye exam at Briargrove Eye Center to review your current care and ask whether lower-maintenance options deserve a place in the conversation.
Why Eye Pressure Rises
Your eye makes a clear liquid called aqueous humor throughout the day. This fluid nourishes the tissues at the front of the eye, flows through the anterior chamber, and exits through drainage structures near the point where the iris and cornea meet.
The trabecular meshwork handles much of this drainage. Picture a fine filter that lets fluid leave the eye at a controlled rate. For many people with open-angle glaucoma or ocular hypertension, fluid moves through this tissue too slowly. The backup can raise intraocular pressure, which eye care professionals often shorten to IOP.
The optic nerve carries visual information from the retina to the brain, much like a bundled data cable. Higher pressure raises the risk of damage to this nerve, yet every eye responds differently. Some people have ocular hypertension, meaning their pressure runs high while the optic nerve remains healthy. Others develop glaucoma while their pressure readings stay within the usual range.
That difference explains why one pressure measurement tells only part of the story. The eye care team also studies optic nerve structure, side vision, corneal health, and changes between visits. Lowering eye pressure remains the central treatment goal because pressure is the glaucoma risk factor that current care can change.
Briargrove Eye Center uses several tools to build that fuller picture. OCT uses light to create detailed, cross-sectional images of the retina and optic nerve. Digital retinal photography records the appearance of the nerve and surrounding tissue. Visual field testing maps peripheral vision and looks for areas where sensitivity has changed. The practice stores retinal images for future comparison, turning separate visits into a timeline of eye health.
That timeline supports early glaucoma detection and helps Dr. Muldoon judge whether eye pressure and optic nerve health appear steady. A change in pressure, nerve tissue, or side vision may lead to a conversation about prescription medicine, sustained-release treatment, SLT, or surgery.
Sustained-Release Implants Handle the Dose
Prescription glaucoma drops place medicine on the surface of the eye. Each dose depends on timing, hand coordination, bottle handling, and consistent technique. Sustained-release eye implants move part of that responsibility inside the eye.
An ophthalmologist places these treatments under sterile conditions. Durysta enters the anterior chamber through an intracameral injection. iDose TR passes through a small corneal incision and anchors within the drainage angle. Both products have U.S. Food and Drug Administration approval for lowering pressure in people with open-angle glaucoma or ocular hypertension.
Once placed, the implant releases pressure-lowering medicine over time. This approach can ease the role of hand strength, daily reminders, bottle storage, and drop technique. It may appeal to someone who struggles to squeeze a bottle, misses doses, or experiences eye-surface irritation during a daily medication routine.
Follow-up care remains central. Pressure checks, corneal evaluations, optic nerve imaging, and visual field tests help the care team study the response and plan the next step.
Durysta Releases Medicine as It Dissolves
Durysta contains 10 micrograms of bimatoprost, a medicine also used in prescription glaucoma drops. An ophthalmologist injects the tiny implant into the anterior chamber, the fluid-filled space between the cornea and iris. The device releases bimatoprost as its biodegradable material gradually breaks down.
The FDA approves Durysta for lowering pressure in people with open-angle glaucoma or ocular hypertension. Current labeling limits treatment to one implant in each treated eye because the implant can affect corneal endothelial cells. These cells line the inner surface of the cornea and help keep it clear.
Before recommending Durysta, an ophthalmologist reviews corneal health, drainage-angle anatomy, lens capsule health, inflammation, infection risk, previous corneal procedures, and the patient’s pressure goal.
The strength and length of the pressure response vary between patients. Some people may use fewer daily drops for a period of time. Others may pair Durysta with another pressure-lowering treatment. Regular exams show how the eye responds and guide future care.
iDose TR Uses a Long-Acting Reservoir
iDose TR takes a different approach. The implant contains 75 micrograms of travoprost, a pressure-lowering medicine from the same family as several glaucoma drops. Its small reservoir releases the medicine from inside the eye.
An ophthalmologist places iDose TR through a small, clear corneal incision and anchors it in the sclera at the iridocorneal angle. The implant stays in place while it delivers travoprost.
A January 2026 FDA update added guidance for repeat treatment. Before readministration, the ophthalmologist measures corneal endothelial cell density and studies the implant, drainage angle, and surrounding eye structures. During the procedure, the surgeon places the new implant first, then removes the previous device. Current labeling sets a maximum of one readministration per year.
This update gives ophthalmologists another way to plan longer-term treatment for suitable patients. Corneal cell health, implant position, glaucoma stage, previous surgery, treatment response, and pressure goals all shape the decision.
Sustained-release eye implants offer one group of alternatives to eye drops, though each product serves patients who meet specific health and anatomy guidelines. Briargrove Eye Center can measure eye pressure, examine the optic nerve, compare OCT scans, map peripheral vision, and share that clinical record during coordinated ophthalmic care.
Laser and MIGS Create New Routes
Sustained-release implants deliver medicine from inside the eye. SLT and MIGS focus on the other side of the pressure equation: drainage.
SLT encourages the eye’s existing drainage tissue to move fluid more freely. MIGS creates a tiny route through tissue that slows fluid flow. Both approaches may reduce the daily medication load for selected patients.
An ophthalmologist performs these treatments. Briargrove Eye Center can document pressure patterns, optic nerve changes, side vision, and cataract status before and after a referral. The practice already provides glaucoma testing and management with OCT, digital retinal imaging, visual field testing, and other diagnostic technology.
SLT Gives Natural Drainage a Boost
Selective laser trabeculoplasty uses brief laser pulses on the trabecular meshwork. The treatment prompts a biological response that helps fluid pass through this drainage tissue more efficiently.
An ophthalmologist places numbing drops in the eye and aims the laser through a special lens. The procedure takes place in an office setting, and the pressure response develops over the following weeks. Follow-up visits help the care team measure the effect. The benefit can fade with time, and some patients receive repeat SLT or combine laser care with prescription medicine.
Doctors now discuss SLT near the beginning of care for many people with ocular hypertension or open-angle glaucoma. The six-year Laser in Glaucoma and Ocular Hypertension Trial compared patients who began treatment with SLT and patients who began with prescription drops.
At six years, 69.8% of eyes in the SLT-first group remained at or below their target pressure while staying free of pressure-lowering medicine and incisional glaucoma surgery. Most drop-free eyes in that group received one or two SLT treatments during the study. Researchers also reported lower rates of disease progression and fewer trabeculectomy and cataract procedures in the SLT-first group.
A 2026 analysis of the trial’s visual field data found a slower average rate of visual field decline among patients who began with SLT. The clearest difference appeared among people with mild glaucoma. These findings support an early conversation about SLT for suitable patients while leaving room for individual pressure goals, anatomy, and treatment response.
For someone who struggles with stiff fingers, hand tremors, eye irritation, or a crowded medication schedule, SLT may remove several daily steps. Caregivers may also find a laser-first plan easier to manage for a parent or family member.
MIGS Adds a Tiny Bypass
Micro-invasive glaucoma surgery, also called minimally invasive glaucoma surgery, covers several procedures that improve fluid drainage through very small openings. Some procedures place microscopic stents in the drainage angle. Others open or remove a narrow section of tissue that restricts fluid flow.
MIGS often suits adults with mild glaucoma. These procedures generally disturb less tissue than traditional glaucoma operations, which can support a faster recovery and a lower risk profile for carefully chosen patients. Glaucoma type, eye anatomy, pressure goals, and treatment history guide the surgeon’s recommendation.
Cataract surgery gives some patients a natural time to discuss MIGS. The ophthalmologist can remove the cloudy lens and add a small drainage route during the same surgical visit.
The iStent inject offers one example. During cataract surgery, the surgeon places two tiny titanium stents through the trabecular meshwork and into Schlemm’s canal, part of the eye’s natural drainage system. The FDA approved the device for adults with mild to moderate primary open-angle glaucoma who also receive cataract surgery.
In the supporting U.S. clinical study, about 76 of every 100 patients who received cataract surgery with iStent inject reached the study’s pressure-lowering benchmark at two years. About 62 of every 100 patients who received cataract surgery alone reached the same benchmark.
MIGS centers on better pressure control. Some patients use fewer glaucoma drops after surgery. Other care plans pair MIGS with medicine, laser treatment, or future procedures as the eyes and pressure goals change.
Briargrove Eye Center can build the detailed record that supports this decision. A timeline of pressure readings, optic nerve images, and side vision results gives the ophthalmologist a clearer view of disease stability and the possible value of surgery.
Smart Glaucoma Care in Uptown Houston
Eye pressure follows a daily tide. It can rise and fall with sleep, body position, activity, medication timing, and other factors. A reading during an eye exam captures one useful moment. Home pressure testing and repeated imaging can add more frames to the film.
Home Pressure Checks Capture More Moments
A home rebound tonometer lets selected patients check their eye pressure at different times. The handheld device uses a small probe to collect a quick reading. The patient’s care team can then study the pattern alongside measurements from the office.
A 2024 pilot study paired home rebound tonometry with virtual reality visual field testing. Home measurements correlated with office results and captured higher maximum pressure readings during the study period. Nine of the 15 participants completed the full home-testing process, showing how training, hand coordination, comfort, and technology access shape the experience.
The study’s small size calls for measured interpretation, yet the approach carries promise. A person whose pressure peaks early in the morning or late at night may bring useful information to the next appointment.
Clinic testing remains the anchor of glaucoma monitoring. OCT imaging, visual field testing, optic nerve evaluation, corneal measurements, and office pressure checks tell the larger story. Home readings may add context for patients who can use the device reliably.
AI Research Connects Images With Function
Artificial intelligence can study patterns across large collections of OCT scans, retinal photographs, and visual field results. Researchers are teaching these systems to connect structural changes in the optic nerve with functional changes in side vision.
A 2026 study used OCT and visual field data from 1,640 patients with glaucoma. Researchers trained three deep-learning models to predict visual field maps from retinal nerve fiber layer measurements captured by OCT. The study points toward a future where imaging software may help clinicians connect nerve tissue measurements with the way a patient sees.
AI remains an active area of research. The optometrist still brings pressure readings, eye anatomy, medical history, treatment response, and the full examination together.
Briargrove Eye Center already uses OCT to create detailed, cross-sectional images of the retina and optic nerve. Digital retinal photography creates a baseline for later comparison, while visual field testing maps peripheral vision. The practice also offers optomap imaging for a wide view of retinal health. Together, these tools help Dr. Muldoon follow changes from one visit to the next.
That timeline can shape the next conversation. Stable pressure, OCT, and visual field findings may support the current plan. A change in one or more measurements may lead to a discussion about sustained-release medicine, SLT, MIGS, or another pressure-lowering choice.
Daily drops now share the treatment menu with long-acting implants, office laser therapy, microscopic drainage procedures, home pressure testing, and detailed imaging. Each option serves a different purpose, and many patients benefit from a thoughtful combination.
Briargrove Eye Center gives patients across Uptown Houston, Tanglewood, the Galleria area, and nearby communities a familiar place to begin. The team can measure eye pressure, examine the optic nerve, compare OCT scans, map side vision, and review how the current treatment fits everyday life.
Request an Eye Exam Today!
Ready to explore a lighter glaucoma routine? Request a comprehensive eye exam at Briargrove Eye Center and ask, “Could sustained-release medicine, SLT, or MIGS fit my care plan?”
A few careful measurements can lead to a more personal strategy. Modern glaucoma care offers more ways to protect sight while giving patients greater freedom from the bottle and the clock.
